Skip to main content
SpringerLink
Log in

Chirurgie optimale des stades avancés : aspects oncologiques

  • Chapter
Les cancers ovariens

Part of the book series: Abord clinique ((ONCOLPRAT))

  • 324 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Meigs J (1934) Tumors of the Female Pelvic Organs. New York, Macmillan, 262–3

    Google Scholar 

  2. Griffiths CT, Parker LM, Fuller AF, Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235–40

    CAS  PubMed  Google Scholar 

  3. Griffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58: 131–42

    CAS  PubMed  Google Scholar 

  4. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101–4

    CAS  PubMed  Google Scholar 

  5. Hacker NF, Berek JS, Lagasse LD et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–20

    CAS  PubMed  Google Scholar 

  6. Pohl R, Dallenbach-Hellweg G, Plugge T, Czernobilsky B (1984) Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol 5: 160–9

    CAS  PubMed  Google Scholar 

  7. Delgado G, Oram DH, Petrilli ES (1984) Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 18: 293–8

    Article  CAS  PubMed  Google Scholar 

  8. Neijt JP, Bokkel Huinink WW, van der Burg ME et al. (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157–68

    CAS  PubMed  Google Scholar 

  9. Seifer DB, Kennedy AW, Webster KD et al. (1988) Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma. Cleve Clin J Med 55: 555–60

    CAS  PubMed  Google Scholar 

  10. Piver MS, Lele SB, Marchetti DL et al. (1988) The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6: 983–9

    CAS  PubMed  Google Scholar 

  11. Sutton GP, Stehman FB, Einhorn LH et al. (1989) Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7: 223–9

    CAS  PubMed  Google Scholar 

  12. Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38: 203–9

    Article  CAS  PubMed  Google Scholar 

  13. Del Campo JM, Felip E, Rubio D et al. (1994) Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 53: 27–32

    PubMed  Google Scholar 

  14. Hoskins WJ, McGuire WP, Brady MF et al. (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974–9

    CAS  PubMed  Google Scholar 

  15. Makar AP, Baekelandt M, Trope CG et al. (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175–80

    Article  CAS  PubMed  Google Scholar 

  16. Scarabelli C, Gallo A, Franceschi S et al. (2000) Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88: 389–97

    Article  CAS  PubMed  Google Scholar 

  17. Chi DS, Liao JB, Leon LF et al. (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: 532–7

    Article  CAS  PubMed  Google Scholar 

  18. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101: 885–91

    Article  PubMed  Google Scholar 

  19. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–33

    CAS  PubMed  Google Scholar 

  20. Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69: 103–8

    Article  CAS  PubMed  Google Scholar 

  21. Alberts DS, Liu PY, Hannigan EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–5

    Article  CAS  PubMed  Google Scholar 

  22. Brun JL, Feyler A, Chene G et al. (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78: 21–7

    Article  CAS  PubMed  Google Scholar 

  23. Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90: 390–6

    Article  PubMed  Google Scholar 

  24. Allen DG, Heintz AP, Touw FW (1995) A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16: 349–56

    CAS  PubMed  Google Scholar 

  25. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–59

    Article  PubMed  Google Scholar 

  26. Eitan R, Levine DA, Abu-Rustum N et al. (2005) The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer

    Google Scholar 

  27. Liu PC, Benjamin I, Morgan MA et al. (1997) Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64: 4–8

    Article  CAS  PubMed  Google Scholar 

  28. Munkarah AR, Hallum AV, Morris M et al. (1997) Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64: 13–7

    Article  CAS  PubMed  Google Scholar 

  29. Bristow RE, Montz FJ, Lagasse LD et al. (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72: 278–87

    Article  CAS  PubMed  Google Scholar 

  30. Curtin JP, Malik R, Venkatraman ES et al. (1997) Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64: 9–12

    Article  CAS  PubMed  Google Scholar 

  31. Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–97

    CAS  PubMed  Google Scholar 

  32. Eisenkop SM, Spirtos NM, Montag TW et al. (1992) The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47: 203–9

    Article  CAS  PubMed  Google Scholar 

  33. Covens AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78: 269–74

    Article  CAS  PubMed  Google Scholar 

  34. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47: 159–66

    Article  CAS  PubMed  Google Scholar 

  35. Hunter RW, Alexander ND, Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166: 504–11

    CAS  PubMed  Google Scholar 

  36. Morice P, Brehier-Ollive D, Rey A et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14: 74–7

    CAS  PubMed  Google Scholar 

  37. Spirtos NM, Gross GM, Freddo JL, Ballon SC (1995) Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 56: 345–52

    Article  CAS  PubMed  Google Scholar 

  38. Le T, Krepart GV, Lotocki RJ, Heywood MS (1997) Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 67: 208–14

    Article  CAS  PubMed  Google Scholar 

  39. Eisenkop SM, Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82: 435–41

    CAS  PubMed  Google Scholar 

  40. van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–34

    PubMed  Google Scholar 

  41. Vergote I, De W, I, Tjalma W et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71: 431–6

    Article  CAS  PubMed  Google Scholar 

  42. Schwartz PE, Rutherford TJ, Chambers JT et al. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72: 93–9

    Article  CAS  PubMed  Google Scholar 

  43. Kuhn W, Rutke S, Spathe K et al. (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92: 2585–91

    Article  CAS  PubMed  Google Scholar 

  44. Kayikcioglu F, Kose MF, Boran N et al. (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. International Journal of Gynecological Cancer 11: 466–70

    CAS  PubMed  Google Scholar 

  45. Fanfani F, Ferrandina G, Corrado G et al. (2003) Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65: 316–22

    Article  PubMed  Google Scholar 

  46. Ansquer Y, Leblanc E, Clough K et al. (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91: 2329–34

    Article  CAS  PubMed  Google Scholar 

  47. Mazzeo F, Berliere M, Kerger J et al. (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90: 163–9

    Article  CAS  PubMed  Google Scholar 

  48. Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–97

    Article  CAS  PubMed  Google Scholar 

  49. Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: 227–31

    Article  CAS  PubMed  Google Scholar 

  50. Vergote IB, De W, I, Decloedt J et al. (2000) Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27: 31–6

    CAS  PubMed  Google Scholar 

  51. Friedman RL, Eisenkop SM, Wang HJ (1997) Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol 67: 88–94

    Article  CAS  PubMed  Google Scholar 

  52. Clough KB, Ladonne JM, Nos C et al. (1999) Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study. Gynecol Oncol 72: 411–7

    Article  CAS  PubMed  Google Scholar 

  53. Ozalp S, Yalcin OT, Dundar E et al. (1999) Second-look laparotomy; factors affecting the results and the prognosis. Eur J Gynaecol Oncol 20: 398–402

    CAS  PubMed  Google Scholar 

  54. Hempling RE, Wesolowski JA, Piver MS (1997) Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival. Ann Surg Oncol 4: 349–54

    Article  CAS  PubMed  Google Scholar 

  55. Cacciari N, Zamagni C, Strocchi E et al. (1999) Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look. Eur J Gynaecol Oncol 20: 56–60

    CAS  PubMed  Google Scholar 

  56. Rubin SC, Randall TC, Armstrong KA et al. (1999) Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93: 21–4

    Article  CAS  PubMed  Google Scholar 

  57. Nicoletto MO, Tumolo S, Talamini R et al. (1997) Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission—a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15: 994–9

    CAS  PubMed  Google Scholar 

  58. Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. International Journal of Gynecological Cancer 13Suppl 2: 149–55

    PubMed  Google Scholar 

  59. Ozols RF (2000) Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 27: 3–7

    CAS  PubMed  Google Scholar 

  60. (1995) NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273: 491–7

    Google Scholar 

  61. Morris M, Gershenson DM, Wharton JT et al. (1989) Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34: 334–8

    Article  CAS  PubMed  Google Scholar 

  62. Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88: 144–53

    Article  CAS  PubMed  Google Scholar 

  63. Segna RA, Dottino PR, Mandeli JP et al. (1993) Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11: 434–9

    CAS  PubMed  Google Scholar 

  64. Tay EH, Grant PT, Gebski V, Hacker NF (2002) Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99: 1008–13

    Article  PubMed  Google Scholar 

  65. Zang RY, Zhang ZY, Li ZT, Chen J et al. (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75: 24–30

    Article  CAS  PubMed  Google Scholar 

  66. Scarabelli C, Gallo A, Carbone A (2001) Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83: 504–12

    Article  CAS  PubMed  Google Scholar 

  67. Eisenkop SM (2004) Commenting on “future directions in the surgical management of ovarian cancer” by Berman 90: s35-39. Gynecol Oncol 94: 235–6

    PubMed  Google Scholar 

  68. Markman M (2001) Intraperitoneal drug delivery of antineoplastics. Drugs 61: 1057–65

    Article  CAS  PubMed  Google Scholar 

  69. Polyzos A, Tsavaris N, Kosmas C et al. (1999) A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56: 291–6

    Article  CAS  PubMed  Google Scholar 

  70. Barakat RR, Sabbatini P, Bhaskaran D et al. (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20: 694–8

    Article  PubMed  Google Scholar 

  71. Markman M, Bundy BN, Alberts DS et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–7

    CAS  PubMed  Google Scholar 

  72. Armstrong DK, Bundy BN, Baergen R et al. (2002) Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Pro Am Soc Clin Oncol abstr 803: 201

    Google Scholar 

  73. Plaisant N, Quenet F, Fabbro M et al. (2004) [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer]. Gynecol Obstet Fertil 32: 391–7

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. P.-E. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Rouanet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Colombo, PE., Rouanet, P. (2006). Chirurgie optimale des stades avancés : aspects oncologiques. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_15

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_15

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation